CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Triple-negative breast cancer (TNBC) is aggressive and lacks effective treatments, causing most breast cancer deaths.
• Chimeric antigen receptor (CAR)-T cell therapy offers a promising immunotherapeutic strategy for TNBC.
• CAR-T cells combine antibody specificity with T cell effector functions.

Purpose of the Study:

• To review CAR-T cell therapy opportunities in solid tumors, focusing on TNBC.
• To discuss emerging targets, clinical trials, and implications for TNBC.
• To highlight key challenges and potential solutions for CAR-T cell therapy in TNBC.

Main Methods:

• Review of current literature on CAR-T cell therapy for solid tumors.
• Analysis of emerging targets, clinical trial data, and challenges in TNBC.
• Exploration of strategies to overcome therapeutic hurdles.

Main Results:

• Optimal target selection is crucial to minimize toxicity.
• Tumor escape mechanisms include antigen loss and heterogeneity.
• Promising targets include TROP2, GD2, ROR1, MUC1, and EpCAM.
• Enhanced persistence and trafficking can be achieved through modified CAR designs.
• Fourth-generation CARs (TRUCKs) and combinatorial approaches may improve efficacy.

Conclusions:

• CAR-T cell therapy holds significant potential for TNBC treatment.
• Addressing challenges like target selection, tumor escape, and the tumor microenvironment is essential.
• Further research and innovative strategies are needed to optimize CAR-T cell therapy for solid tumors like TNBC.